Search

Displaying results 1141 - 1150 of 3917 in total
  1. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    [L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577] … [A262929] On January 3, 2024, fidanacogene elaparvovec was approved by Health Canada under the brand name BEQVEZ for the treatment of adults with moderately severe to severe hemophilia B (congenital

  2. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    [A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying

  3. Drug

    Quinagolide

    go.drugbank.com/drugs/DB09097
    ApprovedWithdrawn

    Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia.

  4. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    [L39544] It was fully approved by the FDA on May 25, 2023. … was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European Commission on

  5. Drug

    Conivaptan

    go.drugbank.com/drugs/DB00872
    Approved

    Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin).

  6. Drug

    Rose bengal

    go.drugbank.com/drugs/DB11182
    ApprovedInvestigational

    A direct cytotoxic effect of Rose bengal on microorganisms and cancer cells has been observed, questioning its potential antitumor actions via intralesional injections.

  7. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Merck has terminated its internal clinical development program for esmirtazapine as of March 2010.

  8. Drug

    Iron Dextran

    go.drugbank.com/drugs/DB00893
    ApprovedInvestigationalVet approved

    Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administ...

  9. Drug

    Docusate

    go.drugbank.com/drugs/DB11089
    Approved

    Docusate is on the World Health Organization's List of Essential Medicines[L5915].

    Products: Non-Habit Forming Stool Softener
  10. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AH...